A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 in Combination With Ezetimibe, Ezetimibe/Rosuvastatin, or Ezetimibe/Bempedoic Acid in Healthy Male and Female Participants 18 to 75 Years of Age With Elevated LDL-C
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs AZD 0780 (Primary) ; Bempedoic acid; Ezetimibe; Rosuvastatin
- Indications Cardiovascular disorders; Dyslipidaemias; Liver disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 03 Jan 2025 Planned End Date changed from 4 Dec 2025 to 5 Dec 2025.
- 03 Jan 2025 Planned primary completion date changed from 4 Dec 2025 to 5 Dec 2025.
- 03 Jan 2025 Status changed from not yet recruiting to recruiting.